Member Info for moonparty

Joaung1, short answer - no, Scancell doesn't use p16-ARC antibodies, as far as I am aware. No mention of them in any Scancell literature.

Also it's adjuvant (post tumour removal), Scope trial is not.

Great results, not relevant for Scannell's scope iscib1+ target market

Very relaxed about news

If financing, even short term, was an issue they would have done a placing by now.

There is clearly a plan, and the sp trajectory indicates it is a value crystallising one.

Perfectly happy to sit back and enjoy a gradual sp rise.

Like taxiing to the runway before take off 😄

Pullback today was bound to happen at some point.

Lots of new shareholders on anything from 10% - 100% profit in the space of days or weeks.

If I was in their position and didn't understand properly what Scancell have I would also be tempted to take some profits.

IMO - as in all bull markets, buy the dips!

Spoke too soon :(

Sellers were in control briefly, normal service has been resumed :)

Just watched, thanks for the link Ray.

Phil did say the therapy works in 80% of patients, and he was talking about the whole patient pool (i.e. scib + modi1).

To me that is a hint that modi1 is doing at least as well as scib. Could be a slip of the tongue, and he only meant for scib, but it didn't come across that way.

Stevenmerret - think you are mistaken, Vulpes have not been trading Scancell, they may have sold and then bought back one time, but they are definitely not trading their stock routinely.

Just for clarification, I'm talking about the share price 😎

To get going 😄

Funny how quickly our expectations change - I'm now disappointed if it's not up B4 breakfast.

Roses, looks like the sell of 486,622 shares at 12:06pm was what dropped the price, not your trades.

They will get hoovered up soon enough.

Interesting that noone is knocking the fundamentals any more. Now technicals is all they have 😄

Chilltime, in the other place, has been saying for months that once the retail gang arrive this will go ballistic.

Kinda obvious, but everyone talks their book. So be wary of folk who want in being negative (whether technically or via 'research').

Also, beware of rampers like me :)

But beware especially of posters new to this board who come along and tout an sp direction. No offence to anyone, TA has it's place (though I don't think it's especially relevant here).

Lots of factors here - end of several large overhangs, news imminent, market and industry waking up to the stunning results, lots of long-term watchers with fomo.

These shares are still very much in demand.

You can sell at least 500,000 for 18.22p, and you can get 18.65 (higher than mid) to sell less than 100k.

But new funds not done buying 😄

The 195000 is not necessarily a fund seller, could easily be a PI selling for a decent profit in a short space of time.

(It's not me, just speculating!)

It does look like the funds are done selling.

There will b e Dancing In The Street if this sp momentum continues

What I meant was I am being offered by the market for my shares, but yes important to get terminology correct re bid/offer or bid/ask if you are American.

Anyway the official bid/offer looks set in for the day now, seems to be a lot of share changing hands at the top end of the 13.5/14 range.

13.81p for 250K (suspect most of the 13.8p-ish trades are actually sells)

13.635 for 500K

Looking good for a blue day

Some musings of my own:

I think there's a good chance of a Nasdaq launch with major funding - Redmile has history.

Any (sensible) investor in the Glycans would want access to Lindy and the technical team, so I suspect any sale here will be only partial, with Scancell retaining a large ownership and technical input.